Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

COMPLEMENTing the diagnosis of aHUS.

Afshar-Kharghan V.

Blood. 2014 Sep 11;124(11):1699-700. doi: 10.1182/blood-2014-07-590356. No abstract available.

2.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

3.

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.

Dorresteijn EM, van de Kar NC, Cransberg K.

Pediatr Nephrol. 2012 Jul;27(7):1193-5. doi: 10.1007/s00467-012-2130-z. Epub 2012 Mar 8.

4.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25.

5.

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.

Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F.

Pediatr Nephrol. 2013 Jan;28(1):155-8. doi: 10.1007/s00467-012-2296-4. Epub 2012 Sep 6.

PMID:
22956028
6.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
7.

Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O.

Pediatr Nephrol. 2013 May;28(5):827-30. doi: 10.1007/s00467-013-2416-9. Epub 2013 Feb 7.

PMID:
23389237
8.

Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Asif A, Nayer A, Haas CS.

J Nephrol. 2017 Jun;30(3):347-362. doi: 10.1007/s40620-016-0357-7. Epub 2016 Nov 15. Review.

9.

Atypical hemolytic uremic syndrome.

Kavanagh D, Goodship TH.

Curr Opin Hematol. 2010 Sep;17(5):432-8. doi: 10.1097/MOH.0b013e32833cae86. Review.

PMID:
20613506
10.

Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.

Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.

Pediatrics. 2014 Jun;133(6):e1759-63. doi: 10.1542/peds.2013-1787.

PMID:
24843059
11.

Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.

Fakhouri F, Frémeaux-Bacchi V, Loirat C.

Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Review.

PMID:
23756030
12.

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P.

Pediatr Nephrol. 2011 Apr;26(4):621-4. doi: 10.1007/s00467-010-1719-3. Epub 2010 Dec 15.

PMID:
21161283
13.

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W.

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060. No abstract available.

PMID:
20445192
14.

Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.

Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.

Pediatrics. 2014 Jun;133(6):e1769-71. doi: 10.1542/peds.2013-2921. Epub 2014 May 19.

PMID:
24843058
15.
16.

Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3.

Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M.

Nefrologia. 2016;36(1):72-5. doi: 10.1016/j.nefro.2015.07.007. Epub 2015 Nov 2. No abstract available.

17.

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.

Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD.

Pediatr Nephrol. 2011 Nov;26(11):2085-8. doi: 10.1007/s00467-011-1989-4. Epub 2011 Aug 30.

18.

Recent advances in the management of atypical hemolytic uremic syndrome.

Cataland SR.

Clin Adv Hematol Oncol. 2012 Aug;10(8):537-9. No abstract available.

PMID:
23073053
19.

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.

Cataland SR, Wu HM.

Blood. 2014 Apr 17;123(16):2478-84. doi: 10.1182/blood-2013-11-516237. Epub 2014 Mar 5.

20.

STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Noris M, Mescia F, Remuzzi G.

Nat Rev Nephrol. 2012 Nov;8(11):622-33. doi: 10.1038/nrneph.2012.195. Epub 2012 Sep 18. Review.

PMID:
22986360

Supplemental Content

Support Center